

Annunziata Nusca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5084502/publications.pdf>

Version: 2024-02-01

27
papers

960
citations

858243

12
h-index

685536

24
g-index

28
all docs

28
docs citations

28
times ranked

1404
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Mediterranean diet on metabolic and inflammatory status of patients with polyvascular atherosclerotic disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 117-124.	1.1	6
2	Prevalence and clinical impact of high platelet reactivity in patients with chronic kidney disease treated with percutaneous coronary intervention: An updated systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1086-1094.	0.7	1
3	In Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches. <i>Life</i> , 2022, 12, 393.	1.1	27
4	Prediction of type 4a myocardial infarction with the angiography-derived hemodynamic (ADDED) index. <i>Heart and Vessels</i> , 2022, 37, 1471-1477.	0.5	1
5	The Role of Angiogenesis and Arteriogenesis in Myocardial Infarction and Coronary Revascularization. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 1024-1048.	1.1	9
6	Invasive Assessment of Coronary Microvascular Function. <i>Journal of Clinical Medicine</i> , 2022, 11, 228.	1.0	17
7	Circadian variations of platelet reactivity on clopidogrel in patients treated with elective percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	1.0	0
8	Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7261.	1.8	4
9	Current management and prognosis of patients with recurrent myocardial infarction. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 731.	0.5	3
10	Prediction of 5-Year Mortality in Patients with Chronic Coronary Syndrome Treated with Elective Percutaneous Coronary Intervention: Role of the ACEF Score. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 1125-1130.	1.1	2
11	Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 670155.	1.6	27
12	Usefulness of Adding Pre-procedural Glycemia to the Mehran Score to Enhance Its Ability to Predict Contrast-induced Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention Development and Validation of a Predictive Model. <i>American Journal of Cardiology</i> , 2021, 155, 16-22.	0.7	10
13	REabsorbable vs. DUrable Polymer Drug-Eluting Stents in All-Coroner PatiEnts: the REDUCE registry. <i>Coronary Artery Disease</i> , 2021, 32, 281-287.	0.3	2
14	Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-9.	1.0	3
15	730 Prediction of type 4a myocardial infarction with the angiography-derived haemodynamic (added) index. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
16	The Pivotal Role of Invasive Functional Assessment in Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA). <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 781485.	1.1	7
17	Changes of the coronary arteries and cardiac microvasculature with aging: Implications for translational research and clinical practice. <i>Mechanisms of Ageing and Development</i> , 2019, 184, 111161.	2.2	30
18	Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention. <i>Cardiovascular Diabetology</i> , 2019, 18, 147.	2.7	29

#	ARTICLE	IF	CITATIONS
19	Relation of Platelet Indexes to Platelet Reactivity and Periprocedural Myocardial Infarction in Patients Who Underwent Percutaneous Coronary Angioplasty. <i>American Journal of Cardiology</i> , 2018, 121, 1027-1031.	0.7	6
20	Early prediction of contrast-induced acute kidney injury by a "bedside" assessment of Neutrophil Gelatinase-Associated Lipocalin during elective percutaneous coronary interventions. <i>PLoS ONE</i> , 2018, 13, e0197833.	1.1	19
21	Glycemic variability in the development of cardiovascular complications in diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e3047.	1.7	109
22	Glycemic Variability Assessed by Continuous Glucose Monitoring and Short-Term Outcome in Diabetic Patients Undergoing Percutaneous Coronary Intervention: An Observational Pilot Study. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-11.	1.0	16
23	Prognostic role of preprocedural glucose levels on short- and long-term outcome in patients undergoing percutaneous coronary revascularization. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 377-384.	0.7	19
24	Platelet Function and Inhibition in Ischemic Heart Disease. <i>Current Cardiology Reports</i> , 2012, 14, 457-467.	1.3	15
25	High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention and Effects on Platelet Inhibition, Endothelial Function, and Inflammation. <i>Journal of the American College of Cardiology</i> , 2011, 57, 771-778.	1.2	77
26	Short-Term, High-Dose Atorvastatin Pretreatment to Prevent Contrast-Induced Nephropathy in		